Core Viewpoint - The company, Suzhou Xinguangyi Electronics Co., Ltd., is set to undergo a significant review by the Shenzhen Stock Exchange after being in the inquiry phase for over two years, with a focus on its financial performance and market position in the high-performance specialty materials sector [1][4]. Group 1: Company Overview - Xinguangyi specializes in the research, production, and sales of high-performance specialty functional materials, with key products including anti-bleeding specialty films and strong resistance specialty films [4]. - The company claims to be the domestic leader in the anti-bleeding specialty film segment, holding the largest market share in China [4]. Group 2: Financial Performance - The company’s main business revenues for 2022, 2023, and 2024 are projected to be 455 million yuan, 516 million yuan, and 657 million yuan, respectively, with net profits of approximately 81.51 million yuan, 83.28 million yuan, and 116 million yuan [5]. - For the first half of 2025, the company reported revenues of 313 million yuan, reflecting a year-on-year increase of 10.24% [5]. Group 3: Profitability and Margin Concerns - Despite revenue and profit growth, the company's gross margin has declined from 38.74% in 2020 to 31.76% in 2022, a drop of about 7 percentage points due to rising raw material costs [6][7]. - The gross margin has remained stable between 31% and 32% during the reporting period, indicating that it has not yet recovered to the 2020 levels [7]. Group 4: Market Dynamics and Risks - The company’s performance is closely tied to the health of downstream industries such as flexible printed circuit boards (FPC), consumer electronics, and new energy lithium batteries, which may face demand fluctuations due to macroeconomic changes [8]. - Xinguangyi has a high customer concentration, with significant sales to major clients like Pengding Holdings and Weixin Electronics, which accounted for 69.64%, 57.22%, and 52.89% of its revenue in recent periods [8]. Group 5: Pricing Trends - The average selling prices of the company's key products, including anti-bleeding specialty films and strong resistance specialty films, have shown a downward trend, particularly with significant price reductions for major clients [10]. - The average selling price for strong resistance specialty films decreased from 3.50 yuan/m² in 2022 to 3.06 yuan/m² in 2024, reflecting a decline of approximately 5% year-on-year [10][11].

Core Viewpoint - The company has announced a delay in the completion of certain fundraising projects, specifically the "Special Functional Materials Industrialization Project" and the "Special Functional Materials R&D Center Project," extending their expected operational status to March 2026 due to various operational and market factors [10][12][13]. Financial Data - The company reported a decline in profits for the first quarter of 2025 compared to the same period last year, attributed to increased costs from trial production and low capacity utilization in subsidiaries [4]. - The company’s total share capital is 139,066,671 shares, with a capital reserve increase of 0.4 shares per share for all shareholders, resulting in a total increase of 55,626,668 shares [3]. Fundraising and Project Status - The total amount raised from the initial public offering was approximately RMB 315.83 million, with a net amount of RMB 295.82 million after expenses [11]. - The company has previously postponed the operational status of the aforementioned projects from March 2024 to June 2025, and now to March 2026, due to stricter requirements in project execution and market demand [12][13]. Use of Funds - The company plans to use RMB 22.82 million of excess fundraising to permanently supplement its working capital, which is 13.60% of the total excess funds raised [31][32]. - The company has committed to ensuring that the use of excess funds will not affect the normal operation of fundraising projects and will comply with regulatory requirements [34][36]. Profit Distribution - The company proposes a profit distribution plan for 2024, which includes a cash dividend of RMB 5.2 per 10 shares and a capital reserve increase of 4 shares for every 10 shares held [41][42]. - The total cash dividend is expected to be approximately RMB 101.24 million, representing 30.20% of the net profit attributable to shareholders for the year [42].